C) interference with biotransformation enzyme activites Reason: The size of the nanoparticle is always in nanoscale 10um to 100nm in which active drug molecules are coated on the neutral chanrged cyclodextrins such as hydroxyl propyl methyl cellulose, methylcellulose in the form of liposomoes. These liposomes can have higher affinity towards the cell membrane negative change and allow the drug molecules to reach the active target regions. These liposomes (acts as surfactant i.e. both hydrophilic & lipophillic properties) can release the drug in controlled level of sustained novel drug delivery systems. Liver biotransformation enzymes are mainly involved in detoxification of foreign materials which are incompatable to the host body therefore, when nanoparticles are going to interact with live CYP enzymes finally reduce toxicity of prodrug or liposome based -nanoparticle drug. Nanoparticles are going to induce toxicity by producing reactive oxygen species (ROS) finally result in oxidative stress due to activation of signaling pathways to cause damage to DNA 1. Pharmaceutical nanoparticle drug delivery in breast cancer chemotherapies include the making the anticancer drug molecules into the “liposome coated” to make efficient drug delivery with efficient bioavailability associated with higher penetration rate into the breast cancer cells. 2. For example “making microRNAs to treat the breast cancer” into the liposome formulation as they can form micelle composed of polymers including methylcellulose, hydroxyl propyl methylcellulose. These polymers have the capability to incorporate the drug moieties into the cancer cells in naoscale. Solution C) interference with biotransformation enzyme activites Reason: The size of the nanoparticle is always in nanoscale 10um to 100nm in which active drug molecules are coated on the neutral chanrged cyclodextrins such as hydroxyl propyl methyl cellulose, methylcellulose in the form of liposomoes. These liposomes can have higher affinity towards the cell membrane negative change and allow the drug molecules to reach the active target regions. These liposomes (acts as surfactant i.e. both hydrophilic & lipophillic properties) can release the drug in controlled level of sustained novel drug delivery systems. Liver biotransformation enzymes are mainly involved in detoxification of foreign materials which are incompatable to the host body therefore, when nanoparticles are going to interact with live CYP enzymes finally reduce toxicity of prodrug or liposome based -nanoparticle drug. Nanoparticles are going to induce toxicity by producing reactive oxygen species (ROS) finally result in oxidative stress due to activation of signaling pathways to cause damage to DNA 1. Pharmaceutical nanoparticle drug delivery in breast cancer chemotherapies include the making the anticancer drug molecules into the “liposome coated” to make efficient drug delivery with efficient bioavailability associated with higher penetration rate i.